×
About 175 results

ALLMedicine™ Factor IX Deficiency Center

Research & Reviews  65 results

The changing treatment landscape in haemophilia: from standard half-life clotting facto...
https://doi.org/10.1016/S0140-6736(20)32722-7
Lancet (London, England); Mancuso ME, Mahlangu JN et. al.

Jan 18th, 2021 - Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chronic ...

Natural history study of factor IX deficiency with focus on treatment and complications...
https://doi.org/10.1111/hae.14139
Haemophilia : the Official Journal of the World Federatio... Shapiro AD, Ragni MV et. al.

Dec 5th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research. B-Natural is a multi-centre, prospective, observational...

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
https://onlinelibrary.wiley.com/doi/10.1111/hae.14139
Haemophilia Shapiro AD

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 no...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667291
Molecular Genetics & Genomic Medicine; Huang L, Li L et. al.

Sep 2nd, 2020 - Hemophilia B (HB) is an X-linked recessive inherited bleeding disorder caused by mutations in the F9 gene that lead to plasma factor IX deficiency. To identify the causative mutations in HB, a molecular analysis of HB pedigrees in China was perfor...

Factor IX Deficiency (Hemophilia B)
https://emedicine.medscape.com/article/199088-overview

Jul 31st, 2019 - Practice Essentials Factor IX (FIX) deficiency or dysfunction, or hemophilia B, is an X-linked inherited bleeding disorder, usually manifested in males and transmitted by females who carry the causative mutation on the X chromosome. Hemophilia B r...

see more →

Guidelines  1 results

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
https://onlinelibrary.wiley.com/doi/10.1111/hae.14139
Haemophilia Shapiro AD

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

see more →

Drugs  11 results see all →

Clinicaltrials.gov  91 results

Alphanine sd - coagulation factor ix (human) kit-GRIFOLS USA, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e99052d-4442-4283-8915-c9a796c77008

Jan 31st, 2021 - AlphaNine SD is indicated for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B. AlphaNine SD contains low, non-therapeutic levels of Factors II, VII, and X, and, therefore, is not indicated for the t...

Profilnine - factor ix complex kit-GRIFOLS USA, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79821042-86a5-4a64-b621-76de0a0bbab2

Jan 31st, 2021 - Profilnine, Factor IX Complex, is indicated for the prevention and control of bleeding in patients with factor IX deficiency (hemophilia B). Profilnine contains non-therapeutic levels of factor VII and is not indicated for use in the treatment of ...

The changing treatment landscape in haemophilia: from standard half-life clotting facto...
https://doi.org/10.1016/S0140-6736(20)32722-7
Lancet (London, England); Mancuso ME, Mahlangu JN et. al.

Jan 18th, 2021 - Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chronic ...

Mononine - coagulation factor ix human kit-CSL Behring LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16f35cdb-7a3b-481b-a25b-0a065aea2c9b

Dec 9th, 2020 - MONONINE is indicated for the prevention and control of bleeding in Factor IX deficiency, also known as Hemophilia B or Christmas disease. MONONINE is not indicated in the treatment or prophylaxis of Hemophilia A patients with inhibitors to Factor...

Natural history study of factor IX deficiency with focus on treatment and complications...
https://doi.org/10.1111/hae.14139
Haemophilia : the Official Journal of the World Federatio... Shapiro AD, Ragni MV et. al.

Dec 5th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research. B-Natural is a multi-centre, prospective, observational...

see more →

News  7 results

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
https://onlinelibrary.wiley.com/doi/10.1111/hae.14139
Haemophilia Shapiro AD

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

CHMP Backs Orphan Drug Refixia for Hemophilia B
https://www.medscape.com/viewarticle/877724

Mar 23rd, 2017 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommend nonacog beta pegol (Refixia, Novo Nordisk A/S) for the treatment and prophylaxis of bleeding in patients aged 12 years and older with hemophili...

Hemophilia B: Lentiviral Vector Safe, Effective in Dogs
https://www.medscape.com/viewarticle/840943

Mar 4th, 2015 - Lentiviral vectors effectively deliver the gene that encodes coagulation factor IX (FIX) to the liver in dogs with naturally occurring hemophilia B (factor IX deficiency), researchers report in an article published in the March 4 issue of Science ...

Rixubis Recommended by EMA Panel for Hemophilia B
https://www.medscape.com/viewarticle/833935

Oct 26th, 2014 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for nonacog gamma (Rixubis, Baxter Innovations GmbH) for prophylaxis and treatment of bleeding in patients...

Rixubis Recommended by EMA Panel for Hemophilia B
https://www.staging.medscape.com/viewarticle/833935

Oct 26th, 2014 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for nonacog gamma (Rixubis, Baxter Innovations GmbH) for prophylaxis and treatment of bleeding in patients...

see more →